Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Assets (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Other Non-Current Assets data on record, last reported at $22.3 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 2690.88% year-over-year to $22.3 million; the TTM value through Dec 2025 reached $22.3 million, up 2690.88%, while the annual FY2025 figure was $22.3 million, 2690.88% up from the prior year.
  • Other Non-Current Assets reached $22.3 million in Q4 2025 per CRNX's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $22.3 million in Q4 2025 and bottomed at $500000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $2.1 million, with a median of $1.3 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: plummeted 38.46% in 2024, then soared 2690.88% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $500000.0 in 2021, then surged by 160.0% to $1.3 million in 2022, then changed by 0.0% to $1.3 million in 2023, then tumbled by 38.46% to $800000.0 in 2024, then skyrocketed by 2690.88% to $22.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $22.3 million in Q4 2025, $1.3 million in Q3 2025, and $1.3 million in Q2 2025.